• Explore /
  • Poster
  • / Association of plasma uracil concentration with 5-FU pharmacokinetics, dose-limiting toxicity, and <em>DPYD</em> genotype in patients with gastrointestinal cancer.

Association of plasma uracil concentration with 5-FU pharmacokinetics, dose-limiting toxicity, and DPYD genotype in patients with gastrointestinal cancer.

Abstract Poster

Authors

null

Gabriel A. Brooks

Dartmouth Cancer Center, Lebanon, NH

Gabriel A. Brooks , Dylan B. Ness , Kathryn Cunningham Hourdequin , Gregory H. Ripple , Manik A. Amin , Sierra Lord-Halvorson , Wahab A. Khan , Sophie J. Deharvengt , Konstantin H. Dragnev , Gregory J. Tsongalis , Wenyan Zhao , Tor D. Tosteson , Lionel D Lewis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 751)

DOI

10.1200/JCO.2024.42.3_suppl.751

Abstract #

751

Poster Bd #

M6

Abstract Disclosures

Similar Posters

First Author: Côme De Metz

First Author: Janet Shirley Graham

First Author: Gabriel Brooks

Poster

2015 Gastrointestinal Cancers Symposium

Therapeutic drug monitoring of 5-fluorouracil (5-FU) in the treatment of patients with colorectal cancer (CRC).

Therapeutic drug monitoring of 5-fluorouracil (5-FU) in the treatment of patients with colorectal cancer (CRC).

First Author: Gaurav Goel